Johnson & Johnson (J&J) ends late-stage HIV vaccine trial; mothers in states with abortion bans are almost 3 times more likely to die before, during, and after birth; Sanofi hopes to release a drug for hemophilia A in 2023.
J&J Will Stop HIV Vaccine Trial
Following evidence of ineffectiveness against infection prevention, Johnson & Johnson (J&J) will discontinue a late-stage worldwide trial of an HIV vaccine, Reuters reported. The news comes over a year after another unsuccessful vaccine study by J&J. A spokesperson who was a partner in the trial said that they will take the information from this trial put it to use in the future. The study started in 2019 at more than 50 locations, comprising about 3900 gay men and transgender people, who are deemed most susceptible to the infection.
States Banning Abortion More Likely to Have Maternal Deaths
Death in women during pregnancy, childbirth, or postpartum is almost 3 times more likely in states with abortion bans, Axios said, after reviewing a report from the Gender Equity Policy Institute. Almost 60% of US women live in states that ban or restrict abortion and other reproductive health care. In 2021, the maternal mortality rate in states with abortion bans was 2.4 times higher than that of states supporting abortion, according to the report, with women of color being the most affected.
Sanofi Strives to Introduce Hemophilia A Drug in 2023
French drug manufacturer Sanofi SA has high hopes for efanesoctocog alfa, its hemophilia A drug, in 2023, according to Reuters. The drug is being created in conjunction with Swedish drug producer Sobi; a decision by the FDA is expected by February 28. The marketing application was accepted by the FDA in 2022. An estimated 400 babies per year are born with the disorder, and possibly more.
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen